4-O-<4-O-(6-O-α-D-Glucopyranosyl-α-D-glucopyranosyl)-α-D-glucopyranosyl>-D-glucose | 34336-93-1

• 物质功能分类: 生物化工 - 糖类化合物 - 寡糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-O-<4-O-(6-O-α-D-Glucopyranosyl-α-D-glucopyranosyl)-α-D-glucopyranosyl>-D-glucose
• 英文别名: Glc1->6Glc1->4Glc1->4Glc；α-isomaltosyl-(1->4)-maltose；6³-α-glucosylmaltotriose；6''-α-D-glucosyl-maltotriose；4-O-α-isomaltosylmaltose；α-D-Glc-(1->6)-α-D-Glc-(1->4)-α-D-Glc-(1->4)-D-Glc；Isomaltosylmaltose；(2S,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6R)-6-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 34336-93-1
• 化学式: C₂₄H₄₂O₂₁
• 分子量: 666.585
• InChiKey: FPBCRLIOSBQLHS-QVTSYAGHSA-N

物化性质

• 熔点：
  172-175°C
• 溶解度：
  可溶于甲醇（轻微加热）、水（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  -9
• 重原子数：
  45
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  348
• 氢给体数：
  14
• 氢受体数：
  21

安全信息

• 储存条件：
  -20°C 冰箱

反应信息

• 作为反应物：
  描述：

  4-O-<4-O-(6-O-α-D-Glucopyranosyl-α-D-glucopyranosyl)-α-D-glucopyranosyl>-D-glucose 在 3-吗啉丙磺酸 、 cycloalternan-forming enzyme from Bacillus sp. NRRL B₂₁₁₉₅ 作用下， 生成 cyclo-{->6)-α-D-Glcp-(1->3)-α-D-Glcp-(1->6)-α-D-Glcp-(1->3)-α-D-Glcp-(1->}
  参考文献：
  名称：

  A synergistic reaction mechanism of a cycloalternan-forming enzyme and a d-glucosyltransferase for the production of cycloalternan in Bacillus sp. NRRL B-21195

  摘要：

  Cycloalternan-forming enzyme (CAFE) was first described as the enzyme that produced cycloalternan from alternan. In this study, we found that a partially purified preparation of CAFE containing two proteins catalyzed the synthesis of cycloalternan from maltooligosaccharides, whereas the purified CAFE alone was unable to do so. In addition to the 117 kDa CAFE itself, the mixture also contained a 140 kDa protein. The latter was found to be a disproportionating enzyme (DE) that catalyzes transfer of a D-glucopyranosyl residue from the non-reducing end of one maltooligosaccharide to the non-reducing end of another, forming an isomaltosyl residue at the non-reducing end. CAFE then transfers the isomaltosyl residue to the non-reducing end of another isomaltosyl maltooligosaccharide, to form an alpha-isomaltosyl-(1-->3)-alpha-isomaltosyl-(1-->4)-maltooligosaccharide, and subsequently catalyzes a cyclization to produce cycloalternan. Thus, DE and CAFE act synergistically to produce cycloalternan directly from maltodextrin or starch. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0008-6215(03)00375-6
• 作为产物：
  描述：

  maltotriose 在 3-吗啉丙磺酸 、 disproportionating enzyme from Bacillus sp. NRRL B-21195 作用下， 反应 160.0h， 生成 4-O-<4-O-(6-O-α-D-Glucopyranosyl-α-D-glucopyranosyl)-α-D-glucopyranosyl>-D-glucose
  参考文献：
  名称：

  A synergistic reaction mechanism of a cycloalternan-forming enzyme and a d-glucosyltransferase for the production of cycloalternan in Bacillus sp. NRRL B-21195

  摘要：

  Cycloalternan-forming enzyme (CAFE) was first described as the enzyme that produced cycloalternan from alternan. In this study, we found that a partially purified preparation of CAFE containing two proteins catalyzed the synthesis of cycloalternan from maltooligosaccharides, whereas the purified CAFE alone was unable to do so. In addition to the 117 kDa CAFE itself, the mixture also contained a 140 kDa protein. The latter was found to be a disproportionating enzyme (DE) that catalyzes transfer of a D-glucopyranosyl residue from the non-reducing end of one maltooligosaccharide to the non-reducing end of another, forming an isomaltosyl residue at the non-reducing end. CAFE then transfers the isomaltosyl residue to the non-reducing end of another isomaltosyl maltooligosaccharide, to form an alpha-isomaltosyl-(1-->3)-alpha-isomaltosyl-(1-->4)-maltooligosaccharide, and subsequently catalyzes a cyclization to produce cycloalternan. Thus, DE and CAFE act synergistically to produce cycloalternan directly from maltodextrin or starch. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0008-6215(03)00375-6

文献信息

• Synthesis from pullulan of spacer-arm, lipid, and ethyl glycosides of a tetrasaccharide [α-d-Glc-(1→6)-α-d-Glc-(1→4)-α-d-Glc-(1→4)-d-Glc] found in human urine; preparation of neoglycoproteins
  作者：Jan Dahmén、Torbjörn Frejd、Göran Magnusson、Ghazi Noori、Anne-Sofie Carlström

  DOI：10.1016/0008-6215(84)85103-4

  日期：1984.4

  2-bromoethanol and boron trifluoride etherate in dichloromethane, gave the 2-bromoethyl glycoside. The reactions of the glycoside with methyl 3-mercaptopropionate, methyl 11-mercaptoundecanoate, and octadecanethiol are described, and also its hydrogenolysis to give an ethyl glycoside. The mercaptopropionate-derived, spacer-arm glycoside has been coupled to bovine serum albumin and keyhole limpet haemocyanin

  摘要支链淀粉的酶水解，然后进行乙酰化和色谱分离，得到乙酰化的α-d -Glc p-（1→6）-α-d -Glc p-（1→4）-α-d -Glc p-（1→ 4）-d-Glc p，其与2-溴乙醇和三氟化硼在二氯甲烷中的醚化产物，得到2-溴乙基糖苷。描述了糖苷与3-巯基丙酸甲酯，11-巯基癸酸甲酯和十八烷硫醇的反应，还对其进行氢解得到乙基糖苷。巯基丙酸酯衍生的间隔臂糖苷已与牛血清白蛋白和匙孔血蓝蛋白偶联。
• Reduction inhibitory agent for active oxygen eliminating activity
  申请人：Oku Kazuyuki

  公开号：US20050123671A1

  公开（公告）日：2005-06-09

  A reduction inhibitory agent for active oxygen eliminating activity which comprises cyclotetrasaccharide i.e., cyclo6}-α-D-glucopyranosyl-(1 3)-α-D-glucopyranosyl-(1 6)-α-D-glucopyranosyl-(1 3)-α-D-glucopyranosyl-(1), as an effective ingredient, a method for inhibiting the reduction of active oxygen eliminating activity which comprises incorporating either cyclotetrasaccharide or the reduction inhibitory agent into plant edible products and/or plant antioxidants, and a composition where the reduction of active oxygen eliminating activity of the plant edible products and/or plant antioxidants has been satisfactorily inhibited by the method.

  一种用于抑制活性氧消除活性的还原抑制剂，其包括环四糖分子即环6}-α-D-葡萄糖苷-(1 3)-α-D-葡萄糖苷-(1 6)-α-D-葡萄糖苷-(1 3)-α-D-葡萄糖苷-(1)作为有效成分，一种用于抑制活性氧消除活性的还原抑制方法，其中包括将环四糖分子或还原抑制剂纳入植物可食用产品和/或植物抗氧化剂中，以及一种组合物，其中通过该方法已经令植物可食用产品和/或植物抗氧化剂的活性氧消除活性得到了令人满意的抑制。
• Reduction inhibitory agent for active oxygen eliminating-activity
  申请人：Oku Kazuyuki

  公开号：US20070218189A1

  公开（公告）日：2007-09-20

  Disclosed are a reduction inhibitory agent for active oxygen eliminating activity, comprising: (a) at least 10% (w/w) of a cyclotetrasaccharide having a basic cyclic structure in Chemical Formula 1, on a dry solid basis; and (b) at least one member selected from the group consisting of saccharides and edible fibers; a method for inhibiting the reduction of active oxygen eliminating activity, comprising a step of incorporating at least one percent (w/w) of a cyclotetrasaccharide having a basic cyclic structure in Chemical Formula 1 to a plant substance, on a dry solid basis, into said plant substance with active oxygen eliminating activity in an aqueous system; and a composition obtainable by incorporating at least one percent (w/w) of a cyclotetrasaccharide having a basic cyclic structure in Chemical Formula 1 to said plant substance, on a dry solid basis, into a plant substance with active oxygen eliminating activity to inhibit the reduction of the activity of said plant substance.

  本发明涉及一种用于抑制活性氧消除活性的还原抑制剂，包括：(a)基于干固体基础上至少10%(w/w)的具有化学式1中的基本环状结构的环四糖；以及(b)至少一种从糖类和可食用纤维组成的群体中选择的成员；一种抑制活性氧消除活性的方法，包括将基于干固体基础上至少1%(w/w)的具有化学式1中的基本环状结构的环四糖加入到具有活性氧消除活性的植物物质中，将该植物物质与环境中的水混合；以及通过将基于干固体基础上至少1%(w/w)的具有化学式1中的基本环状结构的环四糖加入到具有活性氧消除活性的植物物质中，抑制该植物物质活性降低的组合物。
• Präparat zur Wirkstoffapplikation in Kleinsttröpfchenform
  申请人：Cevc, Gregor, Prof. Dr.

  公开号：EP0475160A1

  公开（公告）日：1992-03-18

  Die Erfindung betrifft ein Präparat zur Applikation von Wirkstoffen in Form kleinster, insbesondere mit einer membranartigen Hülle aus einer oder wenigen Lagen amphiphiler Moleküle bzw. mit einer amphiphilen Trägersubstanz versehenen Flüssigkeitströpfchen, insbesondere zum Transport des Wirkstoffes in und durch natürliche Barrieren und Konstriktionen wie Häute und dergleichen. Das Präparat weist einen Gehalt einer randaktiven Substanz auf, der bis zu 99 Mol.-% des Gehaltes dieser Substanz entspricht, durch den der Solubilisierungspunkt der Tröpfchen erreicht wird. Das Präparat eignet sich zur nichtinvasiven Verabreichung von Antidiabetica, insbesondere von Insulin. Die Erfindung betrifft außerdem ein Verfahren zur Herstellung solcher Präparate.

  本发明涉及一种以微小液滴形式施用活性物质的制剂，特别是具有一层或几层两亲性分子或两亲性载体物质的膜状包膜，尤其是用于将活性物质输送到或通过皮肤等天然屏障和收缩物。制剂中边缘活性物质的含量最高可达 99 摩尔%，从而达到液滴的溶解点。该制剂适用于非侵入性给药抗糖尿病药物，特别是胰岛素。本发明还涉及生产这种制剂的工艺。
• Protein particles for therapeutic and diagnostic use
  申请人：——

  公开号：US20020142046A1

  公开（公告）日：2002-10-03

  Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a cross-linking agent and witout denaturation, by the incorporation of a stabilizing agent in the particle composition. Stabilizing agents disclosed include reducing agents, oxdizing agents, hydrogen-accepting molecules, high molecular weight polymers, and sulfur-containing ring compounds. Also disclosed are fibrinogen-coated particles, cross-linked or non-cross-linked, and their use as co-aggregants with platelets and with themselves for purposes of shortening bleeding time and enhancing the effect of thrombin.

  通过在颗粒组合物中加入稳定剂，可使水悬浮液中纳米和微米大小的白蛋白颗粒在不借助交联剂和不发生变性的情况下稳定地防止溶解。已公开的稳定剂包括还原剂、氧化剂、氢接受分子、高分子量聚合物和含硫环化合物。此外，还公开了交联或非交联的纤维蛋白原涂层微粒，以及它们作为与血小板和自身的共聚物的用途，以达到缩短出血时间和增强凝血酶效果的目的。